De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry

Journal of Pathology

Volumn 235, Issue 1, 2015, Pages 3-13

  Balluff, Benjamin ^a   Frese, Christian K ^b   Maier, Stefan K ^c,d   Schöne, Cédrik ^c   Kuster, Bernhard ^d   Schmitt, Manfred ^e   Aubele, Michaela ^c   Höfler, Heinz ^c,e   Deelder, André M ^a   Heck, Albert J R ^b   Hogendoorn, Pancras C W ^a   Morreau, Johannes ^a   Altelaar, A F Maarten ^b   Walch, Axel ^c   McDonnell, Liam A ^a,f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Pisa Science Foundation   (Italy)

Author keywords

Imaging mass spectrometry; Intratumour heterogeneity; Metastasis; Proteomics; Survival

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER RESEARCH; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INTRATUMOUR HETEROGENEITY; LYMPH NODE METASTASIS; MASS SPECTROMETRY; MICRODISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PHYLOGENY; PROTEIN ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TISSUE SECTION; ALGORITHM; BREAST TUMOR; CLUSTER ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; MALE; MORTALITY; PATHOLOGY; PROCEDURES;

ALGORITHMS; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; PHENOTYPE; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84916200561     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4436     Document Type: Article

References (43)

1. Dalerba P, Kalisky T, Sahoo D, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011; 29: 1120-1127.
2. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
3. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-473.
4. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-334.
5. Shibata D. Clonal diversity in tumor progression. Nat Genet 2006; 38: 402-403.
6. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010; 41: 914-917.
7. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
8. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13: e178-185.
9. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-4882.
10. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/ College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007; 25: 5418-5425.
11. Norris JL, Caprioli RM. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 2013; 113: 2309-2342.
12. Walch A, Rauser S, Deininger SO, et al. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol 2008; 130: 421-434.
13. Balluff B, Rauser S, Ebert MP, et al. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology 2012; 143: 544-549, e541-542.
14. McDonnell LA, Corthals GL, Willems SM, et al. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics 2010; 73: 1921-1944.
15. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry - looking beyond classical histology. Nat Rev Cancer 2010; 10: 639-646.
16. Deininger SO, Ebert MP, Futterer A, et al. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J Proteome Res 2008; 7: 5230-5236.
17. Oppenheimer SR, Mi D, Sanders ME, et al. Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res 2010; 9: 2182-2190.
18. Jones EA, Schmitz N, Waaijer CJ, et al. Imaging mass spectrometry-based molecular histology differentiates microscopically identical and heterogeneous tumors. J Proteome Res 2013; 12: 1847-1855.
19. Turtoi A, Blomme A, Debois D, et al. Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology 2014; 59: 924-934.
20. Willems SM, van Remoortere A, van Zeijl R, et al. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol 2010; 222: 400-409.
21. Meding S, Walch A. MALDI imaging mass spectrometry for direct tissue analysis. Methods Mol Biol 2013; 931: 537-546.
22. Norris JL, Cornett DS, Mobley JA, et al. Processing MALDI mass spectra to improve mass spectral direct tissue analysis. Int J Mass Spectrom 2007; 260: 212-221.
23. McDonnell LA, van Remoortere A, de Velde N, et al. Imaging mass spectrometry data reduction: automated feature identification and extraction. J Am Soc Mass Spectrom 2010; 21: 1969-1978.
24. Jones EA, van Remoortere A, van Zeijl RJ, et al. Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One 2011; 6: e24913.
25. Maier SK, Hahne H, Gholami AM, et al. Comprehensive identification of proteins from MALDI imaging. Mol Cell Proteomics 2013; 12: 2901-2910.
26. McDonnell LA, Walch A, Stoeckli M, et al. MSiMass list: a public database of identifications for protein MALDI MS imaging. J Proteome Res 2014; 13: 1138-1142.
27. Nadauld LD, Ford JM. Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol 2013; 31: 838-839.
28. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
29. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
30. Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011; 126: 185-192.
31. Alexandrov T, Chernyavsky I, Becker M, et al. Analysis and interpretation of imaging mass spectrometry data by clustering mass-to-charge images according to their spatial similarity. Anal Chem 2013; 85: 11189-11195.
32. Yap TA, Gerlinger M, Futreal PA, et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps110.
33. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013; 368(9): 842-851.
34. Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010; 16: 681-690.
35. Hardesty WM, Kelley MC, Mi D, et al. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011; 74: 1002-1014.
36. Droin N, Hendra JB, Ducoroy P, et al. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics 2009; 72: 918-927.
37. Mohri Y, Mohri T, Wei W, et al. Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer 2009; 101: 295-302.
38. Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011; 179: 2720-2729.
39. Kim HK, Reyzer ML, Choi IJ, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010; 9: 4123-4130.
40. Aichler M, Elsner M, Ludyga N, et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol 2013; 230: 410-419.
41. Elsner M, Rauser S, Maier S, et al. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J Proteomics 2012; 75: 4693-4704.
42. Dekker TJ, Balluff BD, Jones EA, et al. Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast cancer-associated stroma. J Proteome Res 2014; DOI: 10.1021/pr500253j (in press).
43. Waanders LF, Chwalek K, Monetti M, et al. Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA 2009; 106: 18902-18907.